Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 102 results for "Byetta"

Researchers find anti-diabetic drug not harmful to heart, as previous study found
University of Manitoba

Diabetes drug may help treat cocaine addiction: study

and type 2 diabetics may also help treat cocaine dependence, a new study has claimed. The drug, Byetta, is derived from a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which regulates feeding behaviour. Knowing what they did about ... Business Standard, 2 months ago

Byetta improves liver metabolism in patients with NAFLD

BARCELONA — Byetta, a glucagon-like peptide-1 agonist approved for the treatment of type 2 diabetes mellitus, improved hepatic insulin resistance and adipose tissue in men with nonalcoholic fatty liver disease, according to a poster presentation ...
 Healio2 weeks ago

AstraZeneca PLC AZN: 1st Quarter Results

Q1 2016 Results Financial Summary $m % change --------------------- ------ ---------------- CER(1) Actual --------------------- ------ ------- ------- Total Revenue(2) 6,115 5 1 --------------------- ------ ------- ------- Core(3) Op. Profit ...
 ADVFN UK10 hours ago

Antidiabetics Market 2016-2020 Industry exmined by Syndicate Market Research

Diabetes mellitus, commonly known as diabetes, is a group of metabolic diseases in which blood sugar levels goes extremely high over a prolonged period. Antidiabetics are the medicines developed to stabilize and control blood glucose (sugar) levels ...
 International Business Times2 days ago Global Diabetes Injection Pens Market 2016 Industry Analysis, Segment & Forecast up to 2014 2020  Minyanville3 weeks ago Global Antidiabetics Market 2016 Industry Analysis, Segment & Forecast up to 2014 2020  BioSpace3 weeks ago Diabetes Injection Pens Market - Global Industry Perspective, Comprehensive Analysis and Forecast, 2014 2020  Digital Journal1 month ago
[x]  

Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth

(GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the report to their offering. Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia - high blood glucose levels - that results from defects ...
 Benzinga.com4 days ago Asia-Pacific Type 2 Diabetes Mellitus Therapeutics In Markets To 2021 - Markets Is Expected To Increase In Value At A CAGR Of 7.7%, From $6.07 Billion To Over $10.2 Billion - Research And Markets  TheStreet.com3 days ago Peptide Therapeutics in Metabolic Disorders, 2016 - 2025  MarketResearch.com2 months ago Global Peptide Therapeutics in Metabolic Disorders 2016-2025 [Daily Tribune (Bahrain)]  Pharmacy Choice2 months ago
[x]  

Eli Lilly cuts ties with Transition, ends diabetes drug collaboration

Dive Brief: Eli Lilly has dropped a collaboration deal with Toronto-based Transition Therapeutics, choosing to not advance a type 2 diabetes drug into Phase 3, Transition disclosed on Monday. With this decision, Lilly gives worldwide development ...
 BioPharma Dive1 week ago

Type 2 Diabetes Market To 2019 - A Shifting Treatment Algorithm And Intensified Competition Expected To Drive Growth By 2019

(MENAFN Press) "The Report Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 provides information on pricing market analysis shares forecast and company profiles for key ...
 MENAFN1 week ago Type 2 Diabetes Market to 2019 - Excepted Highest Growth by 2019  Digital Journal1 week ago

List of Sales of Diabetes Drugs in 2015

Trade name Manufacturer Sales/USD100 million Growth Lantus (insulin glargine) Sanofi 71.84 -10.8% Januvia (sitagliptin) MSD 38.63 -2% NovoRapid/NovoLog (insulin aspart/insulin detemir) ...
 CPhI.cn2 weeks ago
Medical News Today

No increased heart failure with incretin-based drugs

Canadian drug safety network provides reassuring evidence regarding risk of heart failure of anti-diabetes medications Incretin-based drugs (which include the DPP-4 inhibitors Galvus, Jalra, Januvia, Nesina, Onglyza, Trajenta, and Xiliarx, as well ...
 Health Canal2 weeks ago Incretin-based drugs do not increase risk of heart failure  News-Medical.Net1 month ago

Novo Nordisk - Growth In 'Diabesity' Treatment (Part 1 Of 2)

Novo Nordisk, the mega-cap Danish pharma company, is experiencing large and growing profits from its glucagon-like receptor agonist Victoza. This agent helps control diabetes, is approved for weight loss, and has also been combined with one of ...
 Seeking Alpha2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less